Guttenplan J B
Mutat Res. 1987 Sep;186(2):81-134. doi: 10.1016/0165-1110(87)90026-1.
Many nitrosamines are potent mutagens. The rate-limiting step in their in vitro metabolism to mutagens is usually a single enzymatic reaction catalyzed by one or more of the many cytochrome P-450-dependent mixed-function oxidases present in the microsomal cell fraction. Current evidence indicates that this reaction activates nitrosamines to alpha-hydroxynitrosamines, which have half-lives on the order of seconds. This product decomposes to an aldehyde and a much shorter-lived ultimate metabolite which is probably an alkyl diazonium ion or an alkyl carbocation. This may react with DNA leading to premutagenic adducts. Such adducts represent a very small fraction of the ultimate mutagen, with the rest reacting with water to yield the corresponding alcohol. Evidence for this pathway includes (1) the observation of deuterium isotope effects in metabolism and mutagenesis, (2) products (aldehydes, alcohols, and N2) consistent with this pathway, (3) studies on metabolism of nitrosamines using purified cytochrome P-450, (4) formation of DNA adducts such as O6-alkylguanines which are consistent with those expected from the ultimate mutagen, (5) expected products and genotoxic effects of other sources of activated nitrosamines, e.g., alpha-acetoxynitrosamines, alkanediazotates and related compounds. Hydroxylation of nitrosamines at other positions also occurs in vitro (usually to a lesser extent), but these products are generally stable and must be further metabolized to exert mutagenic effects (with the exception of N-nitrosoalkyl(formylmethyl)amines, which are direct-acting mutagens). Because only low percentages of nitrosamines are metabolized in vitro, the contribution to mutagenesis by secondary metabolism is small. In this respect, in vitro metabolism can differ significantly from in vivo metabolism. Bacterial mutagenesis by nitrosamines has most often been studied in Salmonella typhimurium and to a lesser extent E. coli. Mutagenesis by nitrosamines generally requires a source of microsomes (a 9000 X g supernatant fraction is often used), and NADPH. Liver fractions from Aroclor-1254- or PB-induced rodents have been most frequently employed but liver fractions from untreated animals, and homogenates of other organs (lung, kidney, nasal mucosa, and pancreas) have also been utilized. Liver homogenates from humans are generally similar to those from untreated rats in metabolizing nitrosamines to mutagens but large interindividual variations are observed. Mutagenesis is often most effective using a liquid preincubation, a slightly acidic incubation mixture and hamster liver fractions.(ABSTRACT TRUNCATED AT 400 WORDS)
许多亚硝胺是强诱变剂。它们在体外代谢为诱变剂的限速步骤通常是由微粒体细胞组分中存在的多种细胞色素P - 450依赖性混合功能氧化酶中的一种或多种催化的单一酶促反应。目前的证据表明,该反应将亚硝胺激活为α-羟基亚硝胺,其半衰期约为几秒。该产物分解为醛和寿命短得多的最终代谢物,后者可能是烷基重氮离子或烷基碳正离子。这可能与DNA反应导致致突变前加合物。这种加合物仅占最终诱变剂的极小部分,其余部分与水反应生成相应的醇。该途径的证据包括:(1)在代谢和诱变中观察到氘同位素效应;(2)与该途径一致的产物(醛、醇和N2);(3)使用纯化的细胞色素P - 450对亚硝胺代谢的研究;(4)形成与最终诱变剂预期一致的DNA加合物,如O6 - 烷基鸟嘌呤;(5)其他活化亚硝胺来源,如α-乙酰氧基亚硝胺、链烷二氮化物及相关化合物的预期产物和遗传毒性效应。亚硝胺在其他位置的羟基化在体外也会发生(通常程度较小),但这些产物一般稳定,必须进一步代谢才能发挥诱变作用(N - 亚硝基烷基(甲酰甲基)胺除外,它是直接作用的诱变剂)。由于只有低百分比的亚硝胺在体外被代谢,二次代谢对诱变的贡献很小。在这方面,体外代谢可能与体内代谢有显著差异。亚硝胺对细菌的诱变作用最常通过鼠伤寒沙门氏菌进行研究,对大肠杆菌的研究较少。亚硝胺诱变通常需要微粒体来源(常使用9000×g上清液组分)和NADPH。最常使用来自经Aroclor - 1254或苯巴比妥诱导的啮齿动物的肝组分,但也使用来自未处理动物的肝组分以及其他器官(肺、肾、鼻粘膜和胰腺)的匀浆。人肝匀浆在将亚硝胺代谢为诱变剂方面通常与未处理大鼠的肝匀浆相似,但个体间存在很大差异。诱变通常在液体预孵育、微酸性孵育混合物和仓鼠肝组分的条件下最有效。(摘要截断于400字)